Modality
Gene Editing
MOA
BCMA ADC
Target
CD3
Pathway
Neuroinflam
Schizophrenia
Development Pipeline
Preclinical
~Nov 2016
→ ~Feb 2018
Phase 1
~May 2018
→ ~Aug 2019
Phase 2
Nov 2019
→ Apr 2031
Phase 2Current
NCT06003393
788 pts·Schizophrenia
2019-11→2031-04·Not yet recruiting
788 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-04-025.0y awayPh3 Readout· Schizophrenia
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P2/3
Not yet…
Catalysts
Ph3 Readout
2031-04-02 · 5.0y away
Schizophrenia
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06003393 | Phase 2/3 | Schizophrenia | Not yet recr... | 788 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| Miriglumide | Alnylam | Phase 3 | CD3 | |
| Talatuximab | Samsung Biologics | Preclinical | CD3 | |
| Sematenlimab | Samsung Biologics | Phase 3 | PI3Kα | |
| MDG-4513 | Madrigal Pharma | Phase 1/2 | CD3 | |
| Tixatapinarof | Recursion | Approved | FGFR |